BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24810493)

  • 1. Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
    Okamoto I; Sakai K; Morita S; Yoshioka H; Kaneda H; Takeda K; Hirashima T; Kogure Y; Kimura T; Takahashi T; Atagi S; Seto T; Sawa T; Yamamoto M; Satouchi M; Okuno M; Nagase S; Takayama K; Tomii K; Maeda T; Oizumi S; Fujii S; Akashi Y; Nishino K; Ebi N; Nakagawa K; Nakanishi Y; Nishio K
    Oncotarget; 2014 Apr; 5(8):2293-304. PubMed ID: 24810493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.
    Okamoto I; Yoshioka H; Morita S; Ando M; Takeda K; Seto T; Yamamoto N; Saka H; Asami K; Hirashima T; Kudoh S; Satouchi M; Ikeda N; Iwamoto Y; Sawa T; Miyazaki M; Tamura K; Kurata T; Fukuoka M; Nakagawa K
    J Clin Oncol; 2010 Dec; 28(36):5240-6. PubMed ID: 21079147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study.
    Yoshioka H; Okamoto I; Morita S; Ando M; Takeda K; Seto T; Yamamoto N; Saka H; Atagi S; Hirashima T; Kudoh S; Satouchi M; Ikeda N; Iwamoto Y; Sawa T; Nakanishi Y; Nakagawa K
    Ann Oncol; 2013 May; 24(5):1326-31. PubMed ID: 23277482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
    Takeda M; Okamoto I; Hirabayashi N; Kitano M; Nakagawa K
    Lung Cancer; 2011 Jul; 73(1):103-9. PubMed ID: 21111509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
    Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
    Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
    Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Owen DH; Williams TM; Bertino EM; Mo X; Webb A; Schweitzer C; Liu T; Roychowdhury S; Timmers CD; Otterson GA
    Lung Cancer; 2019 Aug; 134():167-173. PubMed ID: 31319977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
    Hirsch FR; Varella-Garcia M; Dziadziuszko R; Xiao Y; Gajapathy S; Skokan M; Lin M; O'Neill V; Bunn PA
    Clin Cancer Res; 2008 Oct; 14(19):6317-23. PubMed ID: 18829515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
    Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
    Yokoi T; Minami S; Shiroyama T; Koba T; Torii Y; Sugimoto H; Niki M; Mori M; Morimura O; Hirashima T; Komuta K; Kijima T
    Intern Med; 2019 May; 58(10):1405-1410. PubMed ID: 30713297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
    Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
    Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
    Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
    Kerr KM; Dafni U; Schulze K; Thunnissen E; Bubendorf L; Hager H; Finn S; Biernat W; Vliegen L; Losa JH; Marchetti A; Cheney R; Warth A; Speel EJ; Blackhall F; Monkhorst K; Jantus Lewintre E; Tischler V; Clark C; Bertran-Alamillo J; Meldgaard P; Gately K; Wrona A; Vandenberghe P; Felip E; De Luca G; Savic S; Muley T; Smit EF; Dingemans AC; Priest L; Baas P; Camps C; Weder W; Polydoropoulou V; Geiger TR; Kammler R; Sumiyoshi T; Molina MA; Shames DS; Stahel RA; Peters S;
    Ann Oncol; 2018 Jan; 29(1):200-208. PubMed ID: 29186353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
    Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
    Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.